19

19.00 (0.10%)

As of Nov 07, 2023

INTERCEPT PHARMACEUTICALS, INC. [ICPT]

Source: 

Company Overview

We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases with high unmet medical need utilizing our proprietary bile acid chemistry. Our first marketed product, Ocaliva (obeticholic acid or OCA), is a farnesoid X receptor (FXR) agonist approved in the United States, the European Union and several other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA

CountryUS
Headquartersmorristownnew jersey
Phone Number(646) 747-1000
Industrypharmaceutical preparations
CEOJerome Durso
Websitewww.interceptpharma.com